Math problem with results, page-163

Read section 7......I believe they used those PPA and NPA calculation for only those patient enrolled for that study (i.e. a year later), and didn't combine them (as they are calculated differently......I can't see how they can combine them????). Yes, it's lower but Tony did mention the following......

https://www.fda.gov/RegulatoryInformation/Guidances/ucm071148.htm#7


“The ability to diagnose individual diseases among a cohort of patients experiencing a variety of different respiratory diseases is impressive,” said Dr Paul Porter, Adjunct Associate Professor, Faculty of Health Science, Curtin University, paediatrician and clinical lead at the Joondalup Health Campus study site. “These levels of accuracy will give clinicians significantly more confidence in their treatment decisions, especially in emergency department and telehealth settings.”

“Previous studies have used ResAppDx to diagnose one disease from another. This is the first study where ResAppDx has been used to diagnose a full range of respiratory diseases among a group of patients with a variety of ailments, which is a much greater challenge than previously reported. The excellent results achieved reaffirm the performance of ResAppDx and give us a great deal of confidence as we enter the analysis phase of SMARTCOUGH-C and prepare our de novo submission to the US FDA,” said Dr Tony Keating, CEO and Managing Director of ResApp Health.